We proudly announce that the Infectious Diseases Society of America has selected new data on our investigational therapy zoliflodacin, in uncomplicated gonorrhea for poster presentation at IDWeek 2024. Read more at: www.IDweek.org
Innoviva Specialty Therapeutics, Inc.
Biotechnology Research
Waltham, MA 2,314 followers
About us
Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc., is a biopharmaceutical company developing and delivering innovative therapies in critical care and infectious disease. Our approved treatments are indicated for use in life-threatening circumstances for seriously ill patients, and our investigational therapies are in development for patients fighting drug-resistant pathogens. Growing antimicrobial resistance to existing therapies represents an urgent threat to global public health, and is directly related to significant mortality rates and longer, more expensive hospital stays. We are proud to work with physicians, nurses, hospital pharmacists and administrators, and all who devote their time to caring for patients.
- Website
-
https://innovivaspecialtytherapeutics.com/
External link for Innoviva Specialty Therapeutics, Inc.
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Waltham, MA
- Type
- Privately Held
- Founded
- 2023
- Specialties
- Cardiovascular and Anti-infectives
Locations
-
Primary
35 Gatehouse Drive
Waltham, MA 02451, US
Employees at Innoviva Specialty Therapeutics, Inc.
Updates
-
We’re pleased to announce that our zoliflodacin Phase 3 trial data has been accepted for presentation at this year’s IDWeek Congress. For more information, go to: https://lnkd.in/e6GYRcFg
-
We applaud the Infectious Diseases Society of America (IDSA) for updating its highly valued treatment guidance on antimicrobial-resistant gram-negative infections. As antimicrobial resistance continues to evolve rapidly and create new challenges for healthcare providers, timely dissemination of treatment recommendations is critical in improving patient outcomes. Read more at: https://lnkd.in/dRjmJ_sN
-
We’re excited to announce that eravacycline has received an evidence-based recommendation in the new 2024 SIS cIAI treatment guidelines. For more information, go to: https://lnkd.in/eqvqP_Nc
-
The SIS Therapeutics and Guidelines Committee has just released the much-anticipated 2024 update to the Surgical Infection Society Guidelines on the Management of Intra-Abdominal Infection. Read it in the Surgical Infections journal 👉 https://lnkd.in/dxyFK7-f
-
We’re pleased to welcome Patricia Drake as our new Chief Commercial Officer. To read more, go to https://lnkd.in/eFRjcgVQ
-
We are excited to announce the launch of four new antimicrobial drug susceptibility testing medical devices with our partner, Thermo Fisher Scientific. Together, we are working to bring the latest advances in susceptibility testing technology to ensure flexibility, accuracy, and consistency in the lab. #microbiology, #antibiotic resistance, #IST
-
Read about how we are addressing important challenges and creating new opportunities to enhance patient care in critical care and infectious disease in the June issue of Biopharma Dealmakers. https://lnkd.in/eaSY_PPh